PDS Biotechnology Corporation (PDSB) Stock

PDS Biotechnology Corporation (PDSB) is a Healthcare stock trading at $0.72 (as of 2026-08-05), with a market capitalization of $40.23M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Understand PDS Biotechnology Corporation: how it makes money

PDS Biotechnology develops multifunctional cancer immunotherapies (including PDS0101 for HPV16 associated head and neck and cervical cancers). It is a clinical-stage company with the latest reported revenue of $0.0B, so it is not yet showing commercial sales in the reported quarter.

With no reported revenue, the profit model is driven by clinical success, meaning progress toward approvals would be what enables future commercial revenues and reduces the current operating losses (operating margin -3491%).

Business quality (Unprofitable): Unprofitable (operating margin -3491%).

Bull case

  • Antitumor activity in Versatile 002: Versatile 002 reports an Objective Response Rate and Disease Control Rate, which supports the argument that the approach can produce measurable tumor response and disease control signals.
  • Depth of response implied: The Complete Responses and Complete or Near Complete Responses 90% to 100% Tumor Shrinkage readouts indicate potentially strong disease activity, which is important for immunotherapy differentiation.

Bear case

  • Operating losses are extreme: The company reported an operating margin of -3491%, reflecting substantial ongoing burn before any commercial revenue is visible in the reported quarter.
  • Toxicity and durability uncertainty: The Triple Combination Grade 3 Treatment-Related Adverse Events readout, together with the Checkpoint Inhibitor-Refractory Triple Combination Patients Alive at 12-Month Median Follow-Up label, points to potential tradeoffs between tolerability and sustained benefit in a difficult-to-treat population.
Valuation — source: SEC EDGAR (first-party)
Price$0.72
Market Cap$40.23M
Price / Book10.33
Price / Sales34.11
FCF Yield-104.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.22M
Net Margin-2833.9%
Revenue Growth (YoY)-51.6%
EPS Growth (YoY)-28.2%
FCF Growth (YoY)-20.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-11.44 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($1.50M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOFrank K. Bedu-Addo
Employees24
CountryUS
IPO Date2015-09-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Grace Therapeutics, Inc. (GRCE)
  • FILANA THERAPEUTICS, INC. (FLNA)
  • Seres Therapeutics, Inc. (MCRB)
  • Karyopharm Therapeutics Inc. (KPTI)
  • Silo Pharma, Inc. (SILO)
  • Veru Inc. (VERU)
  • CervoMed Inc. (CRVO)
  • Apollomics, Inc. (APLM)
PDSB earnings history · PDSB institutional & insider holders · PDSB KPIs & operating metrics · PDSB financials · PDSB investor presentations & press releases · PDSB SEC filings · PDSB peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-05.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.